Metachronous Testicular Cancer After Orchiectomy: A Rare Case

Arda, Ersan; Çakıroğlu, Basri; Gül, Çetin; Yuksel, Ilkan

doi:10.7759/cureus.1833

Cited by 4 publications

(1 citation statement)

References 10 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Testicular tumours are rare cancers that comprise only one percent of male malignancies [8]. Although uncommon, screening is important because testicular cancer targets younger men, typically from 15 to 40 years of age, and it has a high cure rate even if the tumour has spread [9]. This high cure rate may be due to the relationship between testicular tumours and immunity [10].…”

Section: Introductionmentioning

confidence: 99%

The Diagnostic Power of the Platelet Mass Index for Testicular Tumours: A Simple Blood Test

Girgin¹,

Çınar²,

Bulut³

et al. 2021

Iberoam J Med

View full text Add to dashboard Cite

Introduction: The relationship between inflammation and cancer has long been the focus of researchers' interest. There are many inflammatory markers studied for this purpose in the literature. In this context, we focused on the effects of platelet counts and platelet mass index (PMI) as inflammatory markers in the diagnosis of low-volume localized testicular cancer. Materials and methods: Thirty-eight patients with localized testicular cancer with a mean age of 30.84 ± 5.79 years and 38 patients with varicocele as a control group with a mean age of 32.8 ± 9.7 years were enrolled in the study. Number of platelets, mean platelet volume and value of PMI were calculated from peripheral blood samples obtained. Results: Number of platelets and PMI values were statistically significantly higher in patients with testicular cancer compared with the control group (p<.05). Conclusions: Both platelet counts and PMI values can be used as a simple test in the diagnosis of testicular cancer besides the well-known accurate serum tumor markers as AFP (alpha fetoprotein), hCG (human chorionic gonadotropin) and LDH (lactate dehydrogenase).

show abstract

Section: Introductionmentioning

confidence: 99%

The Diagnostic Power of the Platelet Mass Index for Testicular Tumours: A Simple Blood Test

Girgin¹,

Çınar²,

Bulut³

et al. 2021

Iberoam J Med

View full text Add to dashboard Cite

show abstract

Oncological and functional outcomes after testis-sparing surgery in patients with germ cell tumors: a systematic review of 285 cases

et al. 2022

View full text Add to dashboard Cite

Introduction and objectives In several urogenital cancers, organ-preserving surgery represents the preferred treatment approach, but in patients with testicular germ cell tumors (tGCTs), radical orchiectomy represents the standard of care. This study aimed to summarize published case series assessing oncological and functional outcomes after testis-sparing surgery (TSS) in patients with tGCTs. Materials and methods A systematic literature review and individual patient data meta-analysis were conducted of published cases with tGCT treated with TSS. Results Of 2,333 reports, we included 32 reports providing data on 285 patients, including 306 testicles treated with TSS. Adjacent germ cell neoplasia in situ (GCNIS) was described in 43%. Hypogonadism and infertility after TSS were diagnosed in 27% and 18%. In patients undergoing adjuvant testicular radiotherapy, hypogonadism was diagnosed in 40%. Patients treated with adjuvant testicular radiotherapy after TSS exhibited a significantly lower incidence of local recurrence (2% vs. 50%, p < 0.001). Distant metastases after TSS were observed in 2%. Conclusion The current data questions the benefits of TSS in tGCT patients. If at all, TSS should only be offered to well-informed patients with a singular testicle, excellent compliance, a singular tumor less than 2 cm located at the lower pole of the testicle, and normal preoperative endocrine function. Unless patients plan to father a child within a short time frame, adjuvant testicular radiotherapy should be recommended after TSS. Radical orchiectomy remains the standard of care, but future studies may support the use of TSS in selected men.

show abstract